ESF-UB Conference in Biomedicine
Nanomedicine: Reality Now and Soon
23-28 October 2010
With Support from |
- Cardiff is one of Britain’s major teaching and research universities. Located in the centre of the capital city of Wales, it has an international reputation for the quality of its work which attracts staff and students from around the world.
- The aim of this proposal is to provide a suitable framework to develop a competitive and high-quality research in Molecular Nanoscience. We intend to take advantage of complementary theoretical and experimental capabilities put in common in this Project to tackle ambitious and high-impact problems in Molecular Nanoscience, which are not possible to solve in the framework of a standard research project.
- IMMUNOSTEP was founded in 2001 following the detection of clear deficiencies in the field of Flow Cytometry. To establish the company, it was necessary to gain the commitment of three social agents: the promotional partners; SODICAL as a provider of risk capital, and the University of Salamanca. Fruit of this tripartite partnership was IMMUNOSTEP, which is housed on one of the floors of the Institute for Cancer Research, adjoint to the University of Salamanca.
- Oryzon is the first Spanish company in functional genomics. Incorporated in 2000, the company is a paradigm of high growth in the emergent Spanish Biotech sector.
- Veeco provides the tools to make, measure and visualize today's world-changing technologies. From LED, solar, data storage, semiconductor and wireless to the frontiers of life science, materials science and nanotechnology, Veeco drives the tiny changes that change everything.
- MEDITRANS represents a multidisciplinary Integrated Project dealing with targeted nanomedicines. Platform technologies will be developed with broad applicability to disease treatment, as exemplified by the choice for chronic inflammatory disorders (rheumatoid arthritis, Crohn’s disease, multiple sclerosis), and cancer as target pathologies.
- Enceladus is a young and small-scale drug development company. Enceladus introduces Nanocort, a liposomal pharmaceutical that contains anti-inflammatory corticosteroid and selectively targets the actual sites of pathology in severe inflammatory disorders such as rheumatoid arthritis (RA) and multiple sclerosis (MS), and in cancer.
